against OspA [6, 8, 10, [17] [18] [19] [20] , OspB [10, 17, 18, 21] , and the 39-kDa protein [16] have been detected in vitro.
To date, OspA and OspB have received the most intense evaluation as potential immunogens [10] [11] [12] [13] [14] [15] , and OspA has emerged as the leading Lyme disease vaccine candidate. Currently, several rOspA formulations are being tested in human vaccine trials [22, 23] . In this report, we characterized the extent and duration of the protective borreliacidal antibody response induced in humans and hamsters after vaccination with a recombinant (r) OspA Lyme disease vaccine [24] . The borreliacidal antibody response was also compared with the total rOspA antibody response detected in humans and hamsters. In addition, we determined the in vitro vaccine-induced borreliacidal activity against B. burgdorferi sensu lato isolates with heterologous OspA sequences representing recently defined seroprotective groups [8, 9] .
Materials and Methods
Human subjects. Eighty-three healthy female and male volunteers 18-60 years old were recruited from the La Crosse area. During the screening visit, persons with medical histories consistent with Lyme disease, known immunodeficiencies, other underlying diseases, or pregnancy were excluded. Prior to vaccination, all volunteers were seronegative for B. burgdorferi antibodies detected by an ELISA (Lyme STAT, Whittaker Bioproducts, Walkersville, MD).
Hamsters. LSH/Ss hamsters (6-10 weeks old) were obtained from a breeding colony at the Wisconsin State Laboratory of Hygiene. Hamsters (60-100 g each) were housed 3 or 4 per cage at an ambient temperature of 21DC. Food and water were available ad libitum. lID 1996; 174 (October) Vaccine. Recombinant lipidated OspA Lyme vaccine was provided by Connaught Laboratories (Swiftwater, PA). The rOspA vaccine was prepared from B. burgdorferi sensu stricto B31 and did not contain adjuvant as previously described [24] . Vaccine for human volunteers was prepared in 1-, 5-, 10-, and 30-J.1.g amounts in 0.5 mL of pyogen-free saline. Vaccine for hamsters was prepared by diluting rOspA with PBS (0.1 M, pH 7.2) to a concentration of 300 J.lg/mL. Hamsters were vaccinated with 0.4 mL of rOspA.
Bacteria and preparation. Low passage « I 0) isolates of B. burgdorferi sensu stricto B31, B. burgdorferi sensu stricto C-I-I I, Borrelia garinii LV4, or Borrelia afzelii BV 1 were grown in modified Barbour-Stoenner-Kelly (BSK) medium [25] at 32°C until reaching a concentration of~10 7 ImL. After incubation, 500-J.lL aliquots of each B. burgdorferi isolate were dispensed into sterile 1.5-mL microfuge tubes (Sarstedt, Princeton, NJ) and frozen at -70°C until used. When needed, a frozen suspension of spirochetes was thawed, and an aliquot was used to inoculate fresh BSK medium. Cultures were incubated at 32°C for 72 h prior to use.
Vaccination and collection of serum. Human volunteers were randomized in a blinded fashion to receive vaccine or a saline placebo. Placebo or 1, 5, 10, or 30 J.1.g of rOspA vaccine was injected intramuscularly into the deltoid muscle. A booster vaccination was administered 30 days after the primary injection. A blood specimen was collected from the volunteers before each vaccination and at 60, 90, and 180 days. Sera were collected and stored at -70°C until used.
Hamsters were vaccinated intramuscularly in the hind thigh with a total of 120 J.1.g of rOspA. A booster vaccination was administered at day 28. At 2, 4, 6, 8, 10, and 30 weeks after vaccination, a group of 3 hamsters each was mildly anesthetized by inhalation of ether contained in a nose-and-mouth cup, and blood was obtained by intracardiac puncture. The blood was allowed to clot, and the serum was separated by centrifugation at 500 g. Serum from the same group of hamsters was pooled and divided into 250-J.lL aliquots and stored at -70°C until used. In addition, serum from nonvaccinated hamsters (n = 3) was pooled and used as a normal serum control.
Assessment ofprotection in hamsters. Fresh cultures of each isolate of B. burgdorferi sensu stricto B31 or C-l-11, B. garinii LV4, or B. afzelii BV1 were diluted with BSK medium to 2.5 X l O" spirochetes/mL. Two weeks after the booster vaccination, separate groups of 3 hamsters were challenged subcutaneously in each hind paw with 0.2 mL of these isolates. Twenty-one days after challenge, hamsters were sacrificed by inhalation of carbon dioxide. The left kidney, spleen, bladder, and heart were aseptically removed and forced through 3-or 5-mL syringes (without a needle) into tubes containing 6 mL of fresh BSK medium. Cultures were vortexed, and 600 J.lL of supernatant was transferred into 5.4 mL (l0% vol/vol) of fresh BSK medium. Cultures were incubated at 32°C for 3 weeks and examined weekly for spirochetes by darkfield microscopy. Samples that remained negative after 3 weeks were concentrated by centrifugation at 5000 g for 5 min; pellets were examined for spirochetes.
Borreliacidal assay. Borreliacidal antibody was detected using a previously described procedure [26] . Briefly, sera were serially 2-fold diluted (hamster, 1:20-1 :20,480; human, I: 10-1: I0,240) in fresh BSK medium. Aliquots (l00 J.lL) of each dilution were transferred to 1.5-mL microfuge tubes (Sarstedt) and heat-inactivated at 56°C for 10 min. Individual cultures of each B. burgdorferi sensu lato isolate were diluted to 10 6 organisms/mL, and 100 f.lL (lOs organisms) of each suspension was added to the microfuge tubes containing diluted sera. Subsequently, 10 Ilol of sterile guinea pig serum (CH so >210 U/mL; Sigma, St. Louis) was added. Assay suspensions were mixed by gentle vortexing and incubated for 18-24 h at 32°C.
After incubation, a 100-J.1L amount was removed from each microfuge tube and diluted 1:5 in sterile PBS (0.0 I M, pH 7.2). Acridine orange (50 f.lL, 5.4 X 10 <) M) was added, and borreliacidal activity was detected using a FACScan single-laser flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). Events were acquired from each sample for 90-120 s in the list mode and analyzed using LYSYS II research software (Becton Dickinson). Forward and side scatter and acridine orange fluorescence were logarithmically amplified and converted to a linear scale for comparison after analysis. The end-point borreliacidal antibody titer was the last dilution with a~16% increase in fluorescence intensity compared with that of a normal serum control [26] .
Expression and purification of OspA. OspA was purified as previously described [8] . Transformed Escherichia coli containing the B. burgdorferi B31 ospA gene were grown in zx tryptoneyeast extract broth containing ampicillin at 37°C for 12 h. Cultures were diluted with fresh broth and incubated for an additional hour. Isopropyl-,B-u-thiogalactopyranoside was added, and cultures were incubated for an additional 5 h. Following incubation, bacteria were centrifuged, resuspended in PBS, and lysed by sonication. Lysed organisms were mixed with Triton X-I 00, diluted with PBS, and centrifuged to remove insoluble material. The supernatant was mixed with a slurry of glutathione-sepharose beads (Pharmacia Biotechnology, Piscataway, NJ) and washed with ice-cold PBS. Fusion proteins were eluted by mixing beads with TRIS-HCI containing reduced glutathione and collected after centrifugation. The elution procedure was repeated four times, and the fractions were analyzed for purity by SDS-PAGE and Western blotting.
ELISA. Purified OspA was diluted to 750 ng/mL in coating buffer (0.015 M Na2C03, 0.035 M NaHC0 3, pH 9.6) and bound to flat-bottom microtiter wells (Dynatech Laboratories, Chantilly, VA). Plates were incubated at 35°C for 4 h followed by an overnight incubation at 4°C. After incubation, plates were washed three times with PBS containing 0.05% Tween 20, sealed, and stored at 4°C. Before use, plates were blocked with PBS containing 1% bovine serum albumin for 30 min at ambient temperature. Plates were then washed twice with PBS-Tween, and 100 f.lL of serum from humans or vaccinated hamsters was serially diluted in PBS and added to individual microtiter wells. Plates were incubated for I h at 23°C and washed three times with PBS-Tween. Goat antihamster IgG or anti-human IgG horseradish peroxidase-conjugated antibodies (Organon Teknika Cappel, Malvern, PA) were diluted I :5000 or 1:3000 in PBS-Tween, respectively. Aliquots (l00 J.lL) of each conjugate were added to respective wells and incubated at 23°C for I h. Subsequently, 100 J.lL ofo-phenylenediamine phosphate (Sigma) was added and incubated at 23°C for 30 min. Reactions were stopped by adding 100 J.lL of 1 N H2S0 4 , and absorbances at 490 nm were immediately determined. The end-point titer was the last dilution with a~0.030 increase III ELISA reactivity compared with prevaccination reactivity. (27) 3 (27) 3 ( 
Results

Borreliacidal antibody response of humans vaccinated with
rOspA. The protective rOspA antibody response was evaluated by determining the in vitro borreliacidal antibody titer after vaccination of human volunteers with one of several doses ofrOspA. The number of respondents and amounts of borreliacidal antibody depended on the dose of rOspA. Borreliacidal antibody was not detectable in sera from persons receiving placebo or 1 J1g of rOspA (data not shown). Killing activity was detectable in some sera from persons receiving 5, 10, or 30 J1g of rOspA (table 1). The highest titers of borreliacidal antibody were detectable 60 days after the primary vaccination (30 days after booster). During this period, borreliacidal activity was detected in 4 (40%) of 10, 8 (80%) of 10, and 9 (81%) of 11 persons receiving 5-, 10-, or 30-J1g doses, respectively. However, borreliacidal activity was most often present only at low titers and quickly waned. Only 1 person (9%) vaccinated with 30 J1g of rOspA had detectable borreliacidal activity 180 days after the primary vaccination.
Total rOspA antibody response of humans vaccinated with rOspA. The total antibody response to rOspA after vaccination of 11 volunteers with 30 J1g of rOspA was determined by ELISA. In contrast to borreliacidal activity, the volunteers (nos. 43-53) vaccinated with 30 J1g rapidly developed antibody to rOspA detectable by ELISA. Significant titers (~1 :80) of ELISA-detectable antibodies were present in sera from 9 vaccinees (81%) at day 60 (table 2) . ELISA reactivity peaked at day 90 (average ELISA titer = 1:1170; range, 1:80-1:5120) and gradually declined. However, significant ELISA reactivity was still detectable in 9 (81 %) of 11 vaccinees after 180 days.
A direct comparison of the protective and total OspA antibody responses using sera from 2 volunteers (nos. 46 and 52) vaccinated with 30 p.,g of rOspA who developed the highest borreliacidal antibody titers confirmed the lack of correlation between the two testing procedures (figure 1).
Borreliacidal activity induced by rOspA against B. burgdor.f eri sensu stricto C-l-ll, B. garinii, and B. afzelii. The ability of vaccination with rOspA from B. burgdorferi B31 to induce borreliacidal antibodies capable of killing other Borrelia isolates was initially examined by determining in vitro borreliacidal activity against isolates of B. burgdorferi sensu lato from 3 additional seroprotective groups [8, 9] . Sera from 30 volunteers participating in an additional clinical vaccination study, each of whom had been vaccinated 60 days previously with 30 p.,g of rOspA from B. burgdorferi B31 and boosted 30 days after the primary vaccination, were screened for borreliacidal antibodies to the vaccine-specific organism. The sera had borreliacidal antibody titers against B31 of 1:20~1:640. However, little or no borreliacidal activity was detectable in vitro against B. burgdorferi sensu stricto C-1-11, B. garinii LV4, or B. afzelii BY1 (table 3) . Borreliacidal antibodies against B. burgdorferi C-l-11, B. garinii, or B. afzelii were detected in 7 (23%), 4 (13%), or 3 (10%) sera, respectively. In addition, borreliacidal activity against these isolates from other seroprotective groups was most often detectable only at low serum dilutions (~1:40).
Borreliacidal and total antibody response after vaccination oj hamsters with rOspA. To confirm the lack of correlation between the protective borreliacidal and total antibody responses, we vaccinated hamsters with the rOspA vaccine. When inbred hamsters were vaccinated with 120 J1g of rOspA, 
NOTE. Sera from 30-day time point were collected immediately prior to booster vaccination. NRD, no response detected. the borreliacidal antibody response was similar to that of humans. Borreliacidal activity was detectable 2-4 weeks after the primary vaccination, peaked 2 weeks after the booster vaccination, and quickly declined (figure 2). Borreliacidal antibody was still detectable in small amounts (1: 160) after week 10 of vaccination but not after week 30 after vaccination, even after vaccination of hamsters with 4-fold higher amounts of rOspA than that given to humans.
The total rOspA antibody response detected by ELISA was also similar to the human response (figure 2). ELISA reactivity increased concurrently with borreliacidal activity. After 6 weeks, total rOspA antibodies began to decrease; however, the ELISA reactivity after this period continued to be significantly elevated compared with borreliacidal activity. A significant OspA antibody response was still detectable by ELISA 30 weeks after vaccination.
Ability ofvaccination with rOspA to provide comprehensive protection in vivo. As with human sera, when sera from hamsters vaccinated with rOspA were incubated with B. burgdor.f eri sensu stricto isolates B3l or C-I-ll, B. garinii, or B. aftelii, only the homologous isolate (B31) was killed by vaccinationinduced borreliacidal antibodies (data not shown). To confirm the inability of vaccination with the rOspA to provide comprehensive protection in vivo, hamsters were vaccinated with 120 j.tg, boosted at week 4, and challenged with B. burgdorferi isolates B3l or C-l-ll, B. garinii LV4, or B. aftelii BVI during the peak protective borreliacidal antibody response (week 6). Immunization provided protection against challenge with B. burgdorferi B3l (table 4) 29], and it is likely that antibody-mediated protection after vaccination with rOspA is due to borreliacidal antibodies. We and colleagues [6] and Fikrig et al. [7] demonstrated that passive transfer of human sera containing OspA borreliacidal antibodies provided protection against infection. More recently, we [8] showed that vaccination of hamsters with rOspA induced borreliacidal antibodies that provided protection against B. burgdorferi infection. Johnson et al. [29] also demonstrated that the ability of vaccination with rOspA to provide protection of recipient hamsters correlated with the borreliacidal activity of the antiserum. As further support, Straubinger et al. [28] vaccinated dogs with an rOspA vaccine identical to the preparation used in this investigation and found a direct correlation between serum-induced growth inhibition of B. burgdorferi in vitro and 6000 NOTE. Spleen, left kidney, and urinary bladder were cultured (3 hamsters/ group).
protection. Collectively, these data are compelling evidence that borreliacidal antibodies are responsible for rOspA-induced immunity.
In this investigation, we characterized the borreliacidal antibody response in human sera after vaccination with a lipidated rOspA vaccine. Borreliacidal antibodies were generally detectable in volunteers after primary and booster vaccination with 30 J.Lg ofrOspA; however, the levels ofborreliacidal antibodies varied widely and borreliacidal activity waned rapidly. Only 1 vaccinee had detectable borreliacidal activity after 180 days. Keller et al. [22] also showed that rOspA vaccine induced antibodies that inhibited the replication of B. burgdorferi; however, the borreliacidal response was short-lived. These investigators suggested that an anamnestic response would provide protection even in the absence of circulating antibodies. Unfor- [28] showed that dogs were protected from challenge with infected ticks 8 weeks after vaccination with rOspA. However, a second challenge with infected ticks several months after vaccination, when borreliacidal antibody levels had waned, produced persistent infection.
These results indicate that the success of an OspA Lyme disease vaccine depends on the ability to induce and maintain high levels of borreliacidal activity. Unfortunately, our results demonstrate that the rOspA vaccine is a poor immunogen for inducing protective borreliacidal antibodies. Although the rOspA vaccine has been shown to be safe [22, 31] , continued efforts are needed to improve its ability to induce and maintain sustained levels of borreliacidal antibodies.
We also found no correlation of the borreliacidal and total anti-rOspA antibody response after vaccination. The antibody responses detected by the borreliacidal antibody test or ELISA were significantly different. High levels of anti-rOspA antibody were still detectable in 82% of vaccinated volunteers after 180 days when the ELISA was used to evaluate the immune response. To confirm the lack of correlation of borreliacidal activity with ELISA reactivity, we vaccinated hamsters with 120 J-lg of rOspA and monitored the antibody responses over time. As with human volunteers, there was no correlation between the borreliacidal and ELISA test results. In addition, the borreliacidal activity was still short-lived despite vaccination with 4-fold more rOspA than given to human volunteers.
These results are not surprising. Creson et al. [32] recently showed that the borreliacidal antibody response after infection of hamsters with B. burgdorferi did not correlate with the antibody responses detected by an indirect fluorescent-antibody assay or Western immunoblotting. Our laboratory [5] have also previously demonstrated that ELISA reactivity does not correlate with the ability to provide protection against infection. Hamsters were passively protected with immune serum containing high levels of borreliacidal antibodies; however, animals became infected when administered serum containing low levels of borreliacidal antibodies despite the presence of high concentrations of antibodies detectable by the ELISA. More recently, Sadziene et al. [33] vaccinated mice with live attenuated B. burgdorferi organisms and evaluated which of the various assays for antibodies to B. burgdorferi provided the best prediction of protection. They confirmed that borreliacidal antibodies appeared early in the course of the immune response and then steadily declined. By contrast, antibodies measured by ELISA were detectable at high levels over months of observation. Most importantly, in vitro borreliacidal activity could predict in vivo protection against challenge with~95% accuracy.
Others have also demonstrated the lack of correlation between vaccine-induced antibody responses detected by functional (borreliacidal antibody test) or matrix-based assays (ELISA) and the inability of high ELISA reactivity to provide protection after vaccination with rOspA. Straubinger et al. [28] demonstrated that high ELISA reactivity in dog serum was not an accurate predictor of immune status. Dogs were not protected after vaccination with rOspA despite high ELISA titers unless high borreliacidal antibody titers were also detectable. Johnson et al. [29] also showed that failure of an rOspA vaccine in hamsters was not associated with lower levels of antibodies detected by ELISA. Hamsters could be readily infected after rOspA vaccination despite developing ELISA titers as high as 1:512,000. Thus, an evaluation of immune status after vaccination with rOspA requires a functional assay to accurately detect anti-OspA antibodies that can kill B. burgdorferi in vitro.
Ma et al. [18] recently provided a likely explanation for this discrepancy. They showed that OspA epitopes that induced borreliacidal antibodies were primarily located near the carboxy-terminus. Other regions of OspA induced other functional types of antibodies that presumably play little role in antibodymediated protection. Detection of these nonborreliacidal antibodies by ELISA could easily confound an immune status determination.
When isolates of B. burgdorferi sensu lato representing different seroprotective groups [8, 9] were incubated in sera from vaccinated humans, only the homologous or vaccine-specific isolate from which the rOspA gene was derived was killed. To confirm these results in vivo, we vaccinated hamsters with 120 j.1,g of rOspA and challenged with 10 4 organisms during the peak borreliacidal response (6 weeks) with the homologous isolate and other B. burgdorferi sensu lato isolates from different seroprotective groups [8, 9] . All isolates except the homologous organism, B. burgdorferi B31, were recovered from rOspA-vaccinated hamsters. These in vivo results correlated with the results obtained by the in vitro borreliacidal assay and confirmed our laboratory's previous findings [8] that a single OspA protein will not provide complete protection against challenge with all Lyme disease spirochetes. These results also highlight the need to assess the functional properties of vaccineinduced antibodies to ensure an accurate assessment of vaccine efficacy.
Fikrig et al. [34] showed that immunization with a single B. burgdorferi protein may be more efficacious than predicted by results from in vitro killing assays or in vivo studies using syringe-mediated challenge. These investigators showed that OspA or OspB immunizations could protect mice from tick-borne infection with heterogeneous B. burgdorferi from different geographic regions. They suggested that protection was more comprehensive than previously reported [8, 9] because destruction of B. burgdorferi within the feeding tick may depend on less specific interactions than those observed within the host. However, it is also possible that comprehensive protection was observed because mice were challenged during the peak borreliacidal antibody response against the homologous isolate and lesser amounts of borreliacidal activity against heterologous isolates were also present. Our group has previously demonstrated borreliacidal activity against heterologous isolates in hamster serum during the peak borreliacidal antibody response [8, 9] . In this investigation, we also detected small amounts of borreliacidal activity against heterologous B. burgdorferi sensu lato in some human sera (table 3) . Borreliacidal activity against heterologous isolates was almost always observed in sera with the highest borreliacidal antibody titers against the vaccine-specific organism (data not shown).
We addressed this further (unpublished data) by vaccinating mice with rOspA from B. burgdorferi sensu stricto 8-1-10 contained in complete Freund's adjuvant as previously described [34] . We then determined the in vitro borreliacidal activity against the homologous and 2 heterologous B. burgdorferi sensu lato isolates and needle-challenged vaccinated animals to assess the ability to protect in vivo. Both the in vitro and in vivo results correlated. During the peak borreliacidal antibody response (6 weeks after primary vaccination, 2 weeks after a second booster), the antibody titer against the vaccinespecific organism was 1:5120. In addition, significant (1:160) borreliacidal activity was also detectable against the heterologous organisms. Correspondingly, none of the mice became infected when needle-challenged with 10 4 of any of the B. burgdorferi isolates. However, 6 weeks later the borreliacidal titers had waned to 1:160 and~I :20 against the homologous and heterologous isolates, respectively. Mice were still protected against challenge with the homologous isolate but became infected when challenged with either of the heterologous isolates. These results further confirm the utility of the in vitro borreliacidal assay for monitoring the efficacy of Lyme disease vaccines.
In conclusion, we showed that vaccination with rOspA induced only a short-lived protective borreliacidal antibody response, even after a booster vaccination. We also demonstrated that vaccination with the rOspA vaccine does not induce protection against heterologous B. burgdorferi sensu lato isolates. Thus, the rOspA vaccine needs to be improved such that high levels of borreliacidal activity can be sustained against B. burgdorferi sensu lato. Unfortunately, improvements will be difficult. The ability of an rOspA vaccine to induce protection against heterologous isolates observed by Fikrig et al. [34] occurred after vaccination with rOspA and an adjuvant. This increased the borreliacidal response to higher levels than were observed with the rOspA vaccine used in this study. Unfortunately, the inclusion of an adjuvant in a human vaccine may cause side effects. Lim and colleagues [35, 36] recently demonstrated the development of severe destructive arthritis in hamsters after vaccination with B. burgdorferi organisms. Thus, the incorporation of multiple OspA proteins from different seroprotective groups may be necessary. To these difficulties must be added the recently recognized ability of B. burgdorferi to regulate the expression of OspA during the attachment and feeding by ticks. During feeding, the spirochete warms to 37°C, down-regulates the expression of OspA, and begins rapid synthesis of OspC [37, 38] . Thus, inclusion of other surface proteins like OspC may also be necessary to maximize protection for the host since all B. burgdorferi organisms may not be susceptible to killing by anti -rOspA borreliacidal antibodies. The heterogeneity and immunogenicity of OspC may also complicate vaccine formulation [39] . As more and more protective antigens are added, we may reinvent the spirochete to produce the adverse effects described by Lim and colleagues [35, 36] .
